Navigation Links
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Date:8/22/2007

Multicenter Study Enrolls More Than 800 Women to Evaluate QuatRx's

New-Generation Selective Estrogen Receptor Modulator (SERM)

ANN ARBOR, Mich., Aug. 22 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene), the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

Ophena(TM) is a new-generation selective estrogen receptor modulator (SERM) for postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal women sometimes referred to as vaginal atrophy and characterized by vaginal symptoms such as dryness, irritation and sexual pain. Phase 2 clinical trials with Ophena(TM) demonstrated beneficial effects on vaginal epithelium and bone markers. In addition, in a Phase 2 trial, Ophena(TM) did not induce hot flashes in postmenopausal women when compared to placebo.

Patient enrollment for the randomized, double-blind study has reached 827 post-menopausal women at 80 trial centers throughout the United States. Women participating in the study are treated with either a 30- or 60-mg once daily oral dose of Ophena(TM) or placebo for 12 weeks. The study is the first of two pivotal Phase 3 efficacy trials planned for the compound.

"Completion of enrollment for this first Ophena(TM) Phase 3 trial is a significant development milestone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "In this pivotal study we are seeking to confirm the beneficial vaginal effects already seen in our Phase 2 program. Millions of women suffer from such post-menopausal symptoms for which there are no oral non-estrogen treatments available. Ophena(TM) is specifically designed to address a major unmet
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Monitoring Patient Glucose Levels: New Advances in software make it easier
6. Managing Preanalytical Processes for Patient Safety
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: Sepsis ... Sepsis patients suffer from a series of diverse ... toxins in the blood or tissues, which cause a ... leading to mortality rates near 50% depending on disease ... national healthcare systems of the global marketplace, which for ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: ... Forecast and Market Analysis to 2022 - Event-Driven Update ... dominated by generics and GlaxoSmithKline,s Benlysta is the only ... more than 50 years. Following Benlysta,s launch, patients, uptake ... price-tag Benlysta has managed to grow the lupus market ...
(Date:5/27/2015)... May 27, 2015 ... the addition of the  "Asia Pacific Ultrasound ... (2014 - 2019)"  company profile to ... , , ,Ultrasound is a type of ... look at body parts and structures inside ...
Breaking Medicine Technology:OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... BMR, TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - ... the,development and commercialization of cancer therapies, today,announced ... team in,Basel, Switzerland validates tenascin as an ... treatments for glioblastoma,multiforme (GBM). , The researchers ...
... BioPharma, Inc.,(Nasdaq:AVII) announced today that its partner Cook ... data from a Phase II clinical trial known ... was designed to study,the effect of the Neugene(R) ... placement of one or more bare metal,stents, in ...
Cached Medicine Technology:Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 2Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 3Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 4AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2
(Date:5/27/2015)... Continuing its commitment to finding a cure and ... SmartPractice® donated $25,000 to HonorHealth Breast Health ... President of Human Resources Meg Mosher and SmartScrubs Director ... Paulla Miller, Sherry Gage, Dr. Linda Greer and Ginger ... April 30. The center is located at 19646 North ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Dr. Omar ... based in Stamford, CT has been selected as part ... first physicians nationwide (and the only physician in Connecticut) ... which allows for the removal of submental fat (double ... no recovery time, no surgery and minimal risks. Dr. ...
(Date:5/27/2015)... NJ (PRWEB) May 27, 2015 ... Network (BCAN) , whose mission is to advance research, ... cancer, have joined forces to battle the fifth most ... in the bladder’s lining start to grow out of ... and their families at every stage of the cancer ...
(Date:5/27/2015)... CompanionDx announced that its abstract “Role ... personalized cancer therapy: Non-small cell lung cancer (NSCLC) case ... Oncology (ASCO) as part of their annual meeting, May ... and clinical data used for the study was obtained ... reports improved patient outcomes from a preliminary analysis of ...
(Date:5/27/2015)... Phoenix, Arizona (PRWEB) May 27, 2015 ... use of their advanced programmatic marketing technology, they have ... provides advertising support on a regional level for seven ... Honda's marketing was through television and radio media. In ... and, with the help of Genius Monkey , ...
Breaking Medicine News(10 mins):Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2
... up to offer customized map solutions. , ... Seattle ... Mapscape B.V. have announced a working relationship that will allow mutual ... solution provided by both companies. , , ,In this relationship, Birdstep ...
... city kids moving, study finds , , FRIDAY, Nov. 14 (HealthDay ... city kids keep excess pounds at bay, according to a ... snapshots in time, and shown that for children in densely ... of obesity. Our new study of over 3,800 inner-city children ...
... treatment and outcomes are different among races , , FRIDAY, Nov. ... have a different genetic makeup in blacks than in whites, ... different among races, a new study says. , In ... of the epidermal growth factor receptor (EGFR) gene and fewer ...
... An intra cellular pathway not previously linked to breast ... is highly lethal and disproportionately over-represented in African American ... destroy proteins and represents a class of genes called ... cells degrade the tumor suppressor gene p27 by making ...
... in Lowering High Blood Pressure Naturally. , ... Phoenix, ... that specializes in all-natural life improvement products, announced the release of ... :Guided Breathing for Low Blood Pressure, this week., , , , ...
... patients more time, developers say , , FRIDAY, Nov. 14 ... developed a technology that can rapidly send an icy ... protect specific organs during certain health emergencies. , ... body through a small intravenous catheter directly into a ...
Cached Medicine News:Health News:Birdstep Technology Partners with Mapscape to Offer RDM Embedded Content Solution for Navigation Systems 2Health News:Birdstep Technology Partners with Mapscape to Offer RDM Embedded Content Solution for Navigation Systems 3Health News:Greener Neighborhoods Mean Slimmer Children 2Health News:Lung Cancer Genetics Different in Black Patients: Study 2Health News:UCLA scientists find cell pathway driving a deadly sub-type of breast cancer 2Health News:UCLA scientists find cell pathway driving a deadly sub-type of breast cancer 3Health News:High Blood-Pressure Patients Can See Improvement Through Guided Breathing 2Health News:IV 'Ice Slurry' Quickly Cools Body for Surgeries 2
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
... Medtronic Ophthalmics offers the most comprehensive ... Eraser Instruments for Cataract incision, Glaucoma ... discrete coagulation is achieved with minimal ... necrosis. Straight eraser styles are available ...
Medicine Products: